Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
Immunexpress.com

Immunexpress to Present Data on SeptiCyte™ at the “Meeting of Experts on Biomarkers to Discriminate Bacterial from Other Infectious Causes of Acute Fever”

SEATTLE, Sept. 16, 2015 –  Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, announced today that Dr. Therese Seldon, Vice President of Operations, will present data on SeptiCyte® technology at the “Meeting of Experts on Biomarkers to Discriminate Bacterial from Other Infectious Causes of...
Immunexpress.com

Immunexpress Supports World Sepsis Day 2015

Call for Action on Sept. 13 Includes Awareness, Education and Funding Initiatives to Help Reverse Global Increase in Numbers of Deaths from Sepsis    Video Interviews on the Immunexpress Website Highlight the Need for Faster Diagnosis of Sepsis  SEATTLE, Sept. 10, 2015 –  Immunexpress, Inc., a molecular diagnostic company committed...
Immunexpress.com

Immunexpress to Present Data on the Early Diagnosis of Sepsis with SeptiCyte™ LAB at the Next Generation Diagnostics Summit

SEATTLE, Aug. 12, 2015 – Immunexpress, Inc. today announced that Dr. Therese Seldon, Vice President of Operations, will present data on the utility of its SeptiCyte® Lab test to aid in the clinical assessment of sepsis in critical care patients at the Next Generation Diagnostics Summit on Aug. 19 in...
Immunexpress.com

Immunexpress to Present Data on Utility of SeptiCyte™ LAB for Diagnosing Sepsis at the Pathology Diagnostics Conference

Immunexpress to Present Data on Utility of SeptiCyte™ Lab for Diagnosing Sepsis at the Pathology Diagnostics Conference SeptiCyte™ Lab Quantifies Host Molecular Markers to Aid Physicians in the Diagnosis of Sepsis in Critical Care Patients SEATTLE, June 4, 2015 – Immunexpress, Inc. today announced that Dr. Antony Rapisarda, Director Medical...
genome web

Immunexpress to Submit Molecular ‘Immune Response’ Sepsis Assay to FDA in May

Immunexpress may finally be close to marketing a clinical test in the US. Having just wrapped up a key clinical trial of its first sepsis assay in around 200 ICU patients, the company plans to submit the test in May to the US Food and Drug Administration and hopes it can...
bioworld-logo

Immunexpress vying for FDA clearance of its sepsis test

When it comes right down to detecting sepsis most diagnostics companies use methods to identify the pathogen. But therein lies the issue with looking for the pathogen, because it has to be in the blood sample or the fluid sample to start with, otherwise a clinician can't find. That's where...
Medcity-news

Immunexpress raising $40M; measures immune response to shave sepsis diagnostic time to one hour

Seattle diagnostics company Immunexpress is working to whittle sepsis screening time down to an hour – and is in the midst of a $40 million Series C to do so.
Immunexpress.com

Immunexpress Receives Early Stage Commercialisation Support to Further Develop SeptiCyte® PLUS

Immunexpress receives Early Stage Commercialisation support to further develop SeptiCyte®PLUS — designed to diagnose sepsis accurately within a clinically relevant timeframe. BRISBANE, Australia (February 18, 2014) – Today, Immunexpress Group (Immunexpress) announced it has received Early Stage Commercialisation support through Commercialisation Australia, an initiative of the Australian Government. The AUD...
Immunexpress.com

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection April 1, 2013 – Today, Immunexpress Group announced the granting of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment” in the European Union (EU). This patent...
Immunexpress.com

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients The MARS Consortium is one of the largest collaborations of academic and industry partners dedicated solely to improving sepsis outcomes SEATTLE, United States / EINDHOVEN, The Netherlands (April 10, 2013) –Today, the Immunexpress Group announced its collaboration...
Immunexpress.com

Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection

Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection SEATTLE, United States (November 21, 2012) – Today, Immunexpress Group announced the granting in the United States (U.S.) of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment.”...
Critical Care

Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis

Sutherland et al., Critical Care | A novel molecular biomarker test based on a panel of 42-gene expression markers has demonstrated a clinically relevant sensitivity and specificity profile, and has the capacity for early detection of sepsis via the monitoring of critical care patients.

If you are a member of the media, please contact:

Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com